Limits...
The use of Yttrium-90 Ibritumomab Tiuxetan ((90)Y-IT) as a consolidation therapy in high-risk patients with diffuse large B-cell lymphoma ineligible for autologous stem-cell transplantation.

Jurczak W, Kisiel E, Sawczuk-Chabin J, Centkowski P, Knopińska-Posłuszny W, Khan O - Contemp Oncol (Pozn) (2015)

Bottom Line: Response rates (CR, PR, SD, PD) according to Cheson criteria, overall survival (OS), progression-free survival (PFS) and adverse effects of radioimmunotherapy were analyzed.During a median follow-up of five years, 11 patients (62%) were alive with no recurrence, 4 patients (22%) were alive with relapse while 3 patients (16%) died.There was no statistically significant difference in PFS between those in CR and those in PR before (90)Y-IT.

View Article: PubMed Central - PubMed

Affiliation: Department of Haematology, Jagiellonian University Collegium Medicum, Krakow, Poland.

ABSTRACT

Aim of the study: To evaluate the efficacy and safety of Yttrium-90 Ibritumomab Tiuxetan ((90)Y-IT) as a consolidation therapy in the management of DLBCL.

Material and methods: Patients with primary refractory or high-risk DLBCL (n = 18), ineligible for autologous stem-cell transplantation, were included in a retrospective study performed at three centers by the Polish Lymphoma Research Group (PLRG). All patients (mean age 61, range 35-82) either didn't achieve a complete response or didn't complete the scheduled therapy due to its complications. Response rates (CR, PR, SD, PD) according to Cheson criteria, overall survival (OS), progression-free survival (PFS) and adverse effects of radioimmunotherapy were analyzed.

Results: Consolidation radioimmunotherapy increased the CR rate from 38% (n = 7) to 82% (n = 15). One patient remained in PR, one patient remained in SD, while one patient remained in PD. During a median follow-up of five years, 11 patients (62%) were alive with no recurrence, 4 patients (22%) were alive with relapse while 3 patients (16%) died. There was no statistically significant difference in PFS between those in CR and those in PR before (90)Y-IT.

Conclusions: Radioimmunotherapy is an effective consolidation therapy for high risk/refractory DLBCL patients and worthy of further investigation in prospective trials.

No MeSH data available.


Related in: MedlinePlus

Progression-free survival (PFS) for all patients (n = 18)
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4507887&req=5

Figure 0001: Progression-free survival (PFS) for all patients (n = 18)

Mentions: A Kaplan-Meier survival analysis determined the PFS and OS at 5 years to be 56% and 82%, respectively (Figs. 1 and 2); the median PFS and OS had not yet been reached. Radioimmunotherapy was more effective if administered early as a consolidation of first-line therapy. The differences in PFS were statistically significant even in such a small group (Fig. 3, p = 0.01 in Gehan's Wilcoxon test). There was no statistically significant difference in PFS between patients previously consolidated in CR and in PR; however, only cases with adequate nodal response (lymph node diameter < 5 cm) qualified. Similarly, bone marrow involvement had no impact on PFS and OS; however, only patients with lymphoma infiltration of less than 15% were included. The use of rituximab with previous chemotherapy regimens seems to have no impact on PFS; however, it is difficult to draw reliable conclusions from such a small group.


The use of Yttrium-90 Ibritumomab Tiuxetan ((90)Y-IT) as a consolidation therapy in high-risk patients with diffuse large B-cell lymphoma ineligible for autologous stem-cell transplantation.

Jurczak W, Kisiel E, Sawczuk-Chabin J, Centkowski P, Knopińska-Posłuszny W, Khan O - Contemp Oncol (Pozn) (2015)

Progression-free survival (PFS) for all patients (n = 18)
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4507887&req=5

Figure 0001: Progression-free survival (PFS) for all patients (n = 18)
Mentions: A Kaplan-Meier survival analysis determined the PFS and OS at 5 years to be 56% and 82%, respectively (Figs. 1 and 2); the median PFS and OS had not yet been reached. Radioimmunotherapy was more effective if administered early as a consolidation of first-line therapy. The differences in PFS were statistically significant even in such a small group (Fig. 3, p = 0.01 in Gehan's Wilcoxon test). There was no statistically significant difference in PFS between patients previously consolidated in CR and in PR; however, only cases with adequate nodal response (lymph node diameter < 5 cm) qualified. Similarly, bone marrow involvement had no impact on PFS and OS; however, only patients with lymphoma infiltration of less than 15% were included. The use of rituximab with previous chemotherapy regimens seems to have no impact on PFS; however, it is difficult to draw reliable conclusions from such a small group.

Bottom Line: Response rates (CR, PR, SD, PD) according to Cheson criteria, overall survival (OS), progression-free survival (PFS) and adverse effects of radioimmunotherapy were analyzed.During a median follow-up of five years, 11 patients (62%) were alive with no recurrence, 4 patients (22%) were alive with relapse while 3 patients (16%) died.There was no statistically significant difference in PFS between those in CR and those in PR before (90)Y-IT.

View Article: PubMed Central - PubMed

Affiliation: Department of Haematology, Jagiellonian University Collegium Medicum, Krakow, Poland.

ABSTRACT

Aim of the study: To evaluate the efficacy and safety of Yttrium-90 Ibritumomab Tiuxetan ((90)Y-IT) as a consolidation therapy in the management of DLBCL.

Material and methods: Patients with primary refractory or high-risk DLBCL (n = 18), ineligible for autologous stem-cell transplantation, were included in a retrospective study performed at three centers by the Polish Lymphoma Research Group (PLRG). All patients (mean age 61, range 35-82) either didn't achieve a complete response or didn't complete the scheduled therapy due to its complications. Response rates (CR, PR, SD, PD) according to Cheson criteria, overall survival (OS), progression-free survival (PFS) and adverse effects of radioimmunotherapy were analyzed.

Results: Consolidation radioimmunotherapy increased the CR rate from 38% (n = 7) to 82% (n = 15). One patient remained in PR, one patient remained in SD, while one patient remained in PD. During a median follow-up of five years, 11 patients (62%) were alive with no recurrence, 4 patients (22%) were alive with relapse while 3 patients (16%) died. There was no statistically significant difference in PFS between those in CR and those in PR before (90)Y-IT.

Conclusions: Radioimmunotherapy is an effective consolidation therapy for high risk/refractory DLBCL patients and worthy of further investigation in prospective trials.

No MeSH data available.


Related in: MedlinePlus